Federal Medical Cannabis Reclassification Challenged by State Attorneys-General
Nebraska, Indiana and Louisiana Attorneys General have taken legal action in order to stop the Federal Government’s decision to change medical cannabis to Schedule III from Schedule I. This lawsuit was filed at the U.S. Court of Appeals in Washington, D.C. Circuit contends the administration has circumvented normal rulemaking processes including public notice and comments periods. Nebraska Examiner. The legal challenge is aimed at stopping the federal reclassification of medical cannabis, which was the subject of diverse reactions from state and federal officials as reported previously by Hemp Gazette.
Nebraska Attorney General Mike Hilgers has voiced his concern that this move, which is a strong opponent to the reclassification of marijuana, could make it easier for the state’s legalization efforts. The marijuana-opposing group Smart Approaches to Marijuana has filed a lawsuit that is similar to the one in question.
The Legal Issues and the Procedural Concerns
The Attorneys’ General argue that the core of their argument is centered on procedural irregularities. Their argument is that the reclassification of medical cannabis by the Obama administration did not follow the normal regulatory framework. This typically requires input from the public and review. In addition, the lawsuit suggests that reclassification could violate an international treaty from 1967 governing drug handling. In order to comply with treaty obligations, the federal agency has suggested a solution. They would purchase medicine from farmers, add a minimal fee and then sell it.
U.S. Attorney Hilgers’ office and U.S. Senator Pete Ricketts has previously fought against medical cannabis laws that were overwhelmingly passed by Nebraska voters 2024. They object to federal medical cannabis reformulation because they believe it will complicate the legal arguments for state-level initiatives. This is especially true as Nebraska Medical Cannabis Commission moves towards setting up cultivation operations. The lawsuit also highlights the fact that Schedule III substances are taxed differently, which could reduce the costs of medical cannabis cultivation in states where the drug is legal.
Reactions in a Political Context
Medical cannabis activists and politicians have criticized the legal challenge. Crista Eggers, of Nebraskans for Medical Marijuana (the group behind the 2024 ballot initiative), said that the advocates had anticipated this legal maneuver. Hilgers’ opponent Jocelyn Brasher in the November general elections, released a statement criticizing the use taxpayer resources to fight the reform. She argued that this interferes with the decisions Nebraska voters, doctors and patients support. WOWT.
The current legal fight highlights the complicated interplay between federal regulation changes, state-level laws, and public sentiment about medical cannabis. The result of the lawsuit may have significant consequences for future regulations of medical cannabis in the United States.
Disclaimer: The information contained in this article does not constitute medical advice. Hemp Gazette is not a medical provider and does not offer diagnoses or treatment plans. Consult a healthcare professional before you make any decision regarding your health. Therapeutic Goods Administration of Australia has not evaluated statements about the therapeutic benefits of cannabinoids, hemp or cannabis. TGA regulations allow Australians to access medical cannabis through prescription.